Document text
Principal Investigator: Neil King
Organization: UNIVERSITY OF WASHINGTON
Fiscal Year: 2024
Award: $41,075,241
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY – OVERALL: MACHINE LEARNING-ENABLED DESIGN OF PROTOTYPE
PATHOGEN VACCINES AND ANTIBODIES
We propose a highly synergistic Center focused on developing end-to-end strategies for pandemic
preparedness vaccine development for bunyaviruses and paramyxoviruses. Our Center brings together five
research institutions with complementary and synergistic expertise in computational protein design,
structure-based vaccine design, mRNA vaccines, structural biology, viral entry, viral diversity and evolution,
animal model development, high biosafety-level containment virology, vaccinology, and vaccine process
development and technology transfer. Our team has real-world experience in vaccine and biologics product
development in both academic and industry settings. Our Center comprises five Scientific Projects supported
by three Scientific Cores, an Administrative Core, and a Data Management Core. Our Scientific Projects
include: 1) Development of computational methods for vaccine and biologics design, 2) Fundamental research
on viral entry and receptors, 3) Antigen design, 4) Protein nanoparticle vaccine development, and 5) mRNA
vaccine development. We will structure our efforts in two phases: in Phase 1 (Years 1-3) we will focus on
developing vaccines for our prototype pathogens and in Phase 2 (Years 4-5) we will apply those learnings to
two new bunyaviruses and two new paramyxoviruses to demonstrate that our computational and experimental
approaches generalize across viral families. Our prototype pathogens are: Lassa virus (LASV; arenaviruses),
Rift Valley fever virus (RVFV; phenuiviruses), and Hendra virus (HeV; paramyxoviruses). We carefully selected
our prototypes as we believe they present specific vaccine design challenges which, if we are successful in
solving, will facilitate the development of vaccines against related viruses. Simultaneously, the antigens from
viruses in these three families have some similarities that will give rise to synergies in our design approaches.
The structure of our Center will allow maximal synergy between our groups in pursuit of its central output: to
define generalizable approaches and tools to develop vaccines and biologics for emerging pathogens with
pandemic potential.
Terms: <2019-nCoV vaccine><Address><Administrative Management><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antigenic Determinants><Antigens><Arenaviridae><Arenavirus><Arenavirus group><Assay><Binding Determinants><Bio-Informatics><Bioassay><Bioinformatics><Biological Agent><Biological Assay><Biological Products><Bunyavirus><COVID-19 vaccine><Clinical Treatment Moab><Communities><Computing Methodologies><Containment><Development><Disease Outbreaks><Electron Microscopy><Ensure><Epitopes><Equine Morbillivirus><Evolution><Family><Generations><Glycoproteins><Hendra Virus><Hendra henipavirus><Human><Immunize><Industry><Institution><Knowledge><Lassa fever virus><Lassa virus><Leadership><Learning><Libraries><Licensure><Machine Learning><Medicine><Membrane><Messenger RNA><Methods><Modeling><Modern Man><Monoclonal Antibodies><Office of Administrative Management><Orthobunyavirus><Outbreaks><Output><Paramyxoviridae><Paramyxovirus><Pathway interactions><Performance><Phase><Process><Production><Protein Engineering><Proteins><Public Health><RNA vaccine><RNA-based vaccine><Receptor Protein><Research><Resolution><Rift Valley fever virus><SARS-CoV-2 vaccine><SARS-coronavirus-2 vaccine><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Structure><Technology><Technology Transfer><Testing><Therapeutic><Vaccine Design><Vaccines><Variant><Variation><Viral><Viral Antigens><Virus><Work><animal model development><biologics><biopharmaceutical><biotherapeutic agent><computational methodology><computational methods><computer based method><computer methods><computing method><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><data management><deliver mRNA><deliver messenger RNA><delivery system for mRNA><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><discover vaccines><emerging pathogen><evaluate vaccines><experience><fundamental research><genetic protein engineering><immunogen><immunogenic><innovate><innovation><innovative><mAbs><mRNA><mRNA delivery><mRNA vaccine><mRNA-based vaccine><machine based learning><machine learning based method><machine learning method><machine learning methodologies><membrane structure><messenger RNA delivery><method development><model development><model developments><model of animal><monoclonal Abs><mutation scanning><mutation screening><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nano particle><nano-sized particle><nanoparticle><nanosized particle><new approaches><new pathogen><next generation><novel><novel approaches><novel pathogen><novel strategies><novel strategy><pandemic concern><pandemic disease preparedness><pandemic planning><pandemic potential><pandemic preparedness><pandemic readiness><pandemic risk><pandemic threat><pathogen><pathway><pre-clinical development><preclinical development><product development><protein design><protein structure prediction><prototype><receptor><resolutions><scaffold><scaffolding><self assembly><structural biology><synergism><tool><tool development><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine antibodies><vaccine candidate><vaccine candidates against SARS-CoV-2><vaccine development><vaccine discovery><vaccine evaluation><vaccine for novel coronavirus><vaccine induced antibodies><vaccine platform><vaccine screening><vaccine strategy><vaccine testing><vaccine-induced antibodies><vaccines preventing COVID><vaccines to prevent COVID><vaccinology><virology><virus antigen>